Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday.

The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share.

Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year.

Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over year.

Also Read:  Could Personalized Medicine Be Your Portfolio’s Next Big Winner? Find Out

Oncology testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter.

Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth.

Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), ...